Gemin X Pharmaceuticals, Inc. Pan Bcl-2 Inhibitor Obatoclax Demonstrates Biological and Clinical Activity in Heavily Pre-Treated Patients with Advanced Chronic Lymphocytic Leukemia

MALVERN, Pa. and MONTREAL, Quebec--(BUSINESS WIRE)--Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that one of its lead oncology candidates, obatoclax, has demonstrated biological and anti-cancer activity in heavily pre-treated patients with advanced chronic lymphocytic leukemia (CLL). The results are from a Phase 1 study, and have been published in the online version of Blood, the Journal of the American Society of Hematology. Full trial results are expected to be published in the upcoming print version of the journal.

Back to news